Boyd Noël van Den Besselaar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Boyd Noël van Den Besselaar has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Aniel Sewnaik
Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam The Netherlands
3 shared publications- Marinella P. J. Offerman
Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam The Netherlands
3 shared publications A. Sewnaik
Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands
2 shared publications- Robert Jan Baatenburg de Jong
Department of Otorhinolaryngology, Head and Neck Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
2 shared publications A. Hoesseini
Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, The Netherlands
1 shared publication- Aimée F. Herkendaal
Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute University Medical Center Rotterdam Rotterdam The Netherlands
1 shared publication
Latest Publications
- Open Access
- 27 April 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 175 (1) , 145-155
Decisional Conflict in Palliative Head and Neck Cancer Patients
Objective: Head and neck cancer (HNC) patients may be subject to decisional conflict (DC). However, research on DC in the palliative phase remains limited. The primary objective of this study was to assess and describe DC among patients with HNC in the palliative phase and explore the association between clinically significant DC and quality of life (QoL). Study design: Prospective cohort study. Setting: Tertiary cancer center. Methods: Patients with HNC entering the palliative phase between September 2022 and March 2024 were eligible. Patients were assessed in 2 cohorts: incurable HNC and refraining from curative treatment. DC was measured using the Decisional Conflict Scale (DCS). Other measures included patient, tumor, and palliative characteristics, and the EORTC QLQ‐C15‐PAL for QoL. Results: Of 104 included patients, 72 patients had incurable HNC and 32 refrained from curative treatment. Clinically significant DC (score ≥25) was observed in 47 incurable HNC patients (65.3%) and 14 patients who refrained from curative treatment (43.8%), which was a significant difference. Tumor stage I/II was significantly predictive of less DC in patients who refrained from curative treatment. Three QoL domains showed large differences for incurable HNC patients when differentiating for clinically significant DC, and 6 for those who refrained from treatment. Conclusion: This study provides valuable insights into DC among palliative HNC patients. Clinically significant DC was more common in patients with incurable HNC than those who refrained from curative treatment. These findings highlight key differences between the cohorts, underscoring the need for tailored counselling to support patient‐centered care.
- 27 April 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 175 (1) , 145-155
Open AccessDecisional Conflict in Palliative Head and Neck Cancer Patients
Objective: Head and neck cancer (HNC) patients may be subject to decisional conflict (DC). However, research on DC in the palliative phase remains limited. The primary objective of this study was to assess and describe DC among patients with HNC in the palliative phase and explore the association between clinically significant DC and quality of life (QoL). Study design: Prospective cohort study. Setting: Tertiary cancer center. Methods: Patients with HNC entering the palliative phase between September 2022 and March 2024 were eligible. Patients were assessed in 2 cohorts: incurable HNC and refraining from curative treatment. DC was measured using the Decisional Conflict Scale (DCS). Other measures included patient, tumor, and palliative characteristics, and the EORTC QLQ‐C15‐PAL for QoL. Results: Of 104 included patients, 72 patients had incurable HNC and 32 refrained from curative treatment. Clinically significant DC (score ≥25) was observed in 47 incurable HNC patients (65.3%) and 14 patients who refrained from curative treatment (43.8%), which was a significant difference. Tumor stage I/II was significantly predictive of less DC in patients who refrained from curative treatment. Three QoL domains showed large differences for incurable HNC patients when differentiating for clinically significant DC, and 6 for those who refrained from treatment. Conclusion: This study provides valuable insights into DC among palliative HNC patients. Clinically significant DC was more common in patients with incurable HNC than those who refrained from curative treatment. These findings highlight key differences between the cohorts, underscoring the need for tailored counselling to support patient‐centered care.
- Open Access
- 13 April 2026
- Published by Association for Computing Machinery (ACM)
- p. 1-6
Exploring AI for enhancing palliative cancer care in remote settings: A co-creation study with healthcare professionals
- 13 April 2026
- Published by Association for Computing Machinery (ACM)
- p. 1-6
Open AccessExploring AI for enhancing palliative cancer care in remote settings: A co-creation study with healthcare professionals
- Open Access
- 24 May 2025
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 282 (9) , 1-9
Validation of the prognostic model “oncologiq palliative” for head and neck cancer patients
Purpose: Patients diagnosed with incurable head and neck squamous cell carcinoma (HNSCC) have a poor prognosis, with a median survival of approximately five months. Physicians often struggle to predict prognosis accurately and tend to overestimate survival. Timely sharing of validated accurate individual information on life expectancy could aid in facilitating better patient counseling. However, this knowledge is lacking. Therefore, the aim of this study is to conduct temporal and external validation of the prognostic model OncologIQ Palliative to assess its accuracy and generalizability. Methods: The validation procedure involved temporal assessment in a retrospective cohort of 355 palliative HNSCC patients from Erasmus MC (2017–2020), followed by external validation in a retrospective cohort of 44 patients from Leiden University Medical Center (2019–2021).The discriminative ability of OncologIQ Palliative was assessed using the C-index and calibration was evaluated through graphical assessment, intercept, and slope. Results: The temporal cohort had a median follow-up of 115 days, and the external cohort 143 days. The model showed moderate discriminative ability in temporal validation (C-index 0.66) and better discrimination in external validation (C-index 0.71). Reasonable agreement was observed between predicted and observed 6-month and 1-year survival rates, with some deviations from the perfect calibration line. Conclusion: The validation methods conducted in this study underscored the reliability of OncologIQ Palliative. They showed adequate calibration and discrimination in both validation procedures, thereby facilitating the provision of more accurate prognostic counselling for head and neck cancer patients in the palliative phase.
- 24 May 2025
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 282 (9) , 1-9
Open AccessValidation of the prognostic model “oncologiq palliative” for head and neck cancer patients
Purpose: Patients diagnosed with incurable head and neck squamous cell carcinoma (HNSCC) have a poor prognosis, with a median survival of approximately five months. Physicians often struggle to predict prognosis accurately and tend to overestimate survival. Timely sharing of validated accurate individual information on life expectancy could aid in facilitating better patient counseling. However, this knowledge is lacking. Therefore, the aim of this study is to conduct temporal and external validation of the prognostic model OncologIQ Palliative to assess its accuracy and generalizability. Methods: The validation procedure involved temporal assessment in a retrospective cohort of 355 palliative HNSCC patients from Erasmus MC (2017–2020), followed by external validation in a retrospective cohort of 44 patients from Leiden University Medical Center (2019–2021).The discriminative ability of OncologIQ Palliative was assessed using the C-index and calibration was evaluated through graphical assessment, intercept, and slope. Results: The temporal cohort had a median follow-up of 115 days, and the external cohort 143 days. The model showed moderate discriminative ability in temporal validation (C-index 0.66) and better discrimination in external validation (C-index 0.71). Reasonable agreement was observed between predicted and observed 6-month and 1-year survival rates, with some deviations from the perfect calibration line. Conclusion: The validation methods conducted in this study underscored the reliability of OncologIQ Palliative. They showed adequate calibration and discrimination in both validation procedures, thereby facilitating the provision of more accurate prognostic counselling for head and neck cancer patients in the palliative phase.
- Open Access
- 10 January 2025
- Published by Springer Nature in BMC Palliative Care
- Vol. 24 (1) , 1-9
A study protocol for individualized prognostic counselling in the palliative phase
Background: Head and neck squamous cell cancer (HNSCC) has a poor prognosis, with approximately 25–30% of patients transitioning into the palliative phase at some point. The length of this phase is relatively short, with a median duration of five months. Patients in this stage often have increased prognostic information needs. Unfortunately, predicting individual life expectancy in this phase is particularly challenging, as physicians and patients tend to overestimate survival. To address this issue, we developed the prognostic model OncologIQ Palliative based on user preferences. In this study, we now aim to assess the clinical impact of utilizing this model during counselling. Methods: This study will employ both quantitative and qualitative approaches. The primary outcome is decisional conflict and satisfaction with the decision-making process after counselling without (cohort 1) and with (cohort 2) OncologIQ Palliative. Therefore, a prospective sequential cohort study will be conducted. Secondary outcomes include the amount of palliative treatment, overall survival rates, and quality of life. These measurements will be collected after the intervention. Additionally, patients’ perspectives on the decision-making process and proactive care planning, including end-of-life discussions, will be explored through interviews. Discussion: By offering more personalized prognostic information for HNSCC patients in the palliative phase, we anticipate a shift towards more patient-centred counselling. This approach can facilitate enhanced end-of-life discussions and better proactive care planning. Patients may experience reduced decisional conflict, feel better prepared for what’s coming, and find assistance in their decision-making process. This could potentially lead to fewer palliative treatments. Overall, these aspects can contribute to a better quality of life and quality of care for HNSCC patients in the last phase of their lives. Trial Registration: This study was registered November 18, 2024, on ClinicalTrials.gov: NCT06699316.
- 10 January 2025
- Published by Springer Nature in BMC Palliative Care
- Vol. 24 (1) , 1-9
Open AccessA study protocol for individualized prognostic counselling in the palliative phase
Background: Head and neck squamous cell cancer (HNSCC) has a poor prognosis, with approximately 25–30% of patients transitioning into the palliative phase at some point. The length of this phase is relatively short, with a median duration of five months. Patients in this stage often have increased prognostic information needs. Unfortunately, predicting individual life expectancy in this phase is particularly challenging, as physicians and patients tend to overestimate survival. To address this issue, we developed the prognostic model OncologIQ Palliative based on user preferences. In this study, we now aim to assess the clinical impact of utilizing this model during counselling. Methods: This study will employ both quantitative and qualitative approaches. The primary outcome is decisional conflict and satisfaction with the decision-making process after counselling without (cohort 1) and with (cohort 2) OncologIQ Palliative. Therefore, a prospective sequential cohort study will be conducted. Secondary outcomes include the amount of palliative treatment, overall survival rates, and quality of life. These measurements will be collected after the intervention. Additionally, patients’ perspectives on the decision-making process and proactive care planning, including end-of-life discussions, will be explored through interviews. Discussion: By offering more personalized prognostic information for HNSCC patients in the palliative phase, we anticipate a shift towards more patient-centred counselling. This approach can facilitate enhanced end-of-life discussions and better proactive care planning. Patients may experience reduced decisional conflict, feel better prepared for what’s coming, and find assistance in their decision-making process. This could potentially lead to fewer palliative treatments. Overall, these aspects can contribute to a better quality of life and quality of care for HNSCC patients in the last phase of their lives. Trial Registration: This study was registered November 18, 2024, on ClinicalTrials.gov: NCT06699316.
- 15 February 2024
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 150 (4) , 303-310
Causes and Ways of Death in Patients With Head and Neck Cancer
Question What are the causes and ways of death in patients with head and neck cancer (HNC)? Findings In this retrospective cohort study of 2180 patients with HNC, 1291 died during follow-up, of whom 557 (43.1%) died due to HNC-related consequences and 734 (56.9%) died of competing causes. Palliative sedation and euthanasia were more common in patients with HNC as the underlying cause of death and in those with a higher socioeconomic status. Meaning The results of this study potentially illuminate causes and ways of death in patients with HNC and support health care professionals in providing more patient-centered care, particularly for those in the palliative phase. Importance There is limited literature on the exact causes and ways of death in patients with head and neck cancer. To provide optimal care, especially in the palliative phase, more information on this is needed. Objective To provide insights into the causes and ways of death among patients with head and neck cancer. Design, Setting, and Participants This retrospective cohort study included a consecutive population of patients who received a diagnosis of primary squamous cell carcinoma of the head and neck between January 2006 and December 2013 who were treated in the Erasmus MC. Patient data were merged with nonpublic microdata from Statistics Netherlands. Follow-up time was specified as the date of diagnosis until death or December 3, 2019, whichever came first. The data were checked and reanalyzed in November 2023. Main outcomes and Measures Causes (eg, head and neck cancer, other cancer) and ways (eg, natural death, suicide) of death. Results A total of 1291 patients (59.2%; 342 women [26.5%]) died during follow-up (median [IQR] follow-up, 2.7 [1.2-5.6] years). The main cause of death was head and neck cancer (557 [43.1%]), followed by the competing cause of other cancers (344 [26.6%]). In total, 240 patients (18.6%) received palliative sedation and 70 patients (5.4%) euthanasia. Compared with patients with head and neck cancer as the underlying cause of death, lower odds ratios (ORs) were observed for receiving palliative sedation (OR, 0.32 vs 0.07; 95% CI, 0.22-0.46 vs 0.03-0.12) and euthanasia (OR, 0.22 vs 0.01; 95% CI, 0.11-0.41 vs 0-0.107) in patients with other causes of death. Patients with a middle and high income had higher ORs for receiving palliative sedation (OR, 1.46 vs 1.86; 95% CI, 1.05-2.04 vs 1.22-2.85) or euthanasia (OR, 2.25 vs 3.37; 95% CI, 1.18-4.3, 1.6-7.12) compared with low-income patients. Retired patients had lower ORs for receiving palliative sedation or euthanasia compared with employed patients (OR, 0.56 vs 0.44; 95% CI, 0.39-0.8 vs 0.24-0.82). Conclusion and Relevance The results of this cohort study suggest that more than half of the patients died of competing causes and palliative sedation and euthanasia were more common in patients with head and neck cancer as the underlying cause of death. Patients with a higher socioeconomic status had higher odds of receiving palliative sedation and euthanasia. These insights may support health care professionals in providing patient-centered care, especially for patients in the palliative phase.
- 15 February 2024
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 150 (4) , 303-310
Causes and Ways of Death in Patients With Head and Neck Cancer
Question What are the causes and ways of death in patients with head and neck cancer (HNC)? Findings In this retrospective cohort study of 2180 patients with HNC, 1291 died during follow-up, of whom 557 (43.1%) died due to HNC-related consequences and 734 (56.9%) died of competing causes. Palliative sedation and euthanasia were more common in patients with HNC as the underlying cause of death and in those with a higher socioeconomic status. Meaning The results of this study potentially illuminate causes and ways of death in patients with HNC and support health care professionals in providing more patient-centered care, particularly for those in the palliative phase. Importance There is limited literature on the exact causes and ways of death in patients with head and neck cancer. To provide optimal care, especially in the palliative phase, more information on this is needed. Objective To provide insights into the causes and ways of death among patients with head and neck cancer. Design, Setting, and Participants This retrospective cohort study included a consecutive population of patients who received a diagnosis of primary squamous cell carcinoma of the head and neck between January 2006 and December 2013 who were treated in the Erasmus MC. Patient data were merged with nonpublic microdata from Statistics Netherlands. Follow-up time was specified as the date of diagnosis until death or December 3, 2019, whichever came first. The data were checked and reanalyzed in November 2023. Main outcomes and Measures Causes (eg, head and neck cancer, other cancer) and ways (eg, natural death, suicide) of death. Results A total of 1291 patients (59.2%; 342 women [26.5%]) died during follow-up (median [IQR] follow-up, 2.7 [1.2-5.6] years). The main cause of death was head and neck cancer (557 [43.1%]), followed by the competing cause of other cancers (344 [26.6%]). In total, 240 patients (18.6%) received palliative sedation and 70 patients (5.4%) euthanasia. Compared with patients with head and neck cancer as the underlying cause of death, lower odds ratios (ORs) were observed for receiving palliative sedation (OR, 0.32 vs 0.07; 95% CI, 0.22-0.46 vs 0.03-0.12) and euthanasia (OR, 0.22 vs 0.01; 95% CI, 0.11-0.41 vs 0-0.107) in patients with other causes of death. Patients with a middle and high income had higher ORs for receiving palliative sedation (OR, 1.46 vs 1.86; 95% CI, 1.05-2.04 vs 1.22-2.85) or euthanasia (OR, 2.25 vs 3.37; 95% CI, 1.18-4.3, 1.6-7.12) compared with low-income patients. Retired patients had lower ORs for receiving palliative sedation or euthanasia compared with employed patients (OR, 0.56 vs 0.44; 95% CI, 0.39-0.8 vs 0.24-0.82). Conclusion and Relevance The results of this cohort study suggest that more than half of the patients died of competing causes and palliative sedation and euthanasia were more common in patients with head and neck cancer as the underlying cause of death. Patients with a higher socioeconomic status had higher odds of receiving palliative sedation and euthanasia. These insights may support health care professionals in providing patient-centered care, especially for patients in the palliative phase.
- Open Access
- 5 September 2023
- Published by Springer Nature in Research Square
Experience with eHealth in the palliative care pathway for head and neck cancer patients – a mixed-methods study
Purpose Our Expert Center of Palliative Care for head and neck cancer offers structural attention to patients’ complex physical and psychosocial care needs. Patients are offered remote care to enable them to stay as long as possible in their trusted home environment. This includes digital monitoring using patient-reported outcome measures. Our research adds to the limited literature on qualitative feedback and patient-reported experiences with palliative HNC care. Methods In this mixed-methods study we evaluated our palliative care pathway. In total, 56 head and neck cancer patients in the palliative care phase and 49 next-of-kin were included. We evaluated their experiences with a patient-reported experience measure that included open questions. Results The face-to-face consultations on the day of the palliative diagnosis were positively experienced by most patients and next-of-kin. One-third missed at least one topic during these consultations, such as discussing life expectancy. During the remote follow-up, the majority felt safe with this care: they were able to sufficiently clarify their problems and, if necessary, timely action was taken. However, 35% of patients and 46% of next-of-kin considered the provided psychosocial support to be insufficient. Conclusion Patients and next-of-kin were satisfied with most aspects of the palliative care, and remote care seems a promising means of delivery. Key areas needing attention are discussing life expectancy and providing psychosocial support. Future research will focus on better understanding patients’ needs during specific moments in the palliative trajectory to optimally deliver personalized and value-based healthcare.
- 5 September 2023
- Published by Springer Nature in Research Square
Open AccessExperience with eHealth in the palliative care pathway for head and neck cancer patients – a mixed-methods study
Purpose Our Expert Center of Palliative Care for head and neck cancer offers structural attention to patients’ complex physical and psychosocial care needs. Patients are offered remote care to enable them to stay as long as possible in their trusted home environment. This includes digital monitoring using patient-reported outcome measures. Our research adds to the limited literature on qualitative feedback and patient-reported experiences with palliative HNC care. Methods In this mixed-methods study we evaluated our palliative care pathway. In total, 56 head and neck cancer patients in the palliative care phase and 49 next-of-kin were included. We evaluated their experiences with a patient-reported experience measure that included open questions. Results The face-to-face consultations on the day of the palliative diagnosis were positively experienced by most patients and next-of-kin. One-third missed at least one topic during these consultations, such as discussing life expectancy. During the remote follow-up, the majority felt safe with this care: they were able to sufficiently clarify their problems and, if necessary, timely action was taken. However, 35% of patients and 46% of next-of-kin considered the provided psychosocial support to be insufficient. Conclusion Patients and next-of-kin were satisfied with most aspects of the palliative care, and remote care seems a promising means of delivery. Key areas needing attention are discussing life expectancy and providing psychosocial support. Future research will focus on better understanding patients’ needs during specific moments in the palliative trajectory to optimally deliver personalized and value-based healthcare.